

**DECISION OF THE EEA JOINT COMMITTEE****No 18/2016****of 5 February 2016****amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2017/1301]**

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area ('the EEA Agreement'), and in particular Article 98 thereof,

Whereas:

- (1) Commission Implementing Regulation (EU) 2015/1981 of 4 November 2015 approving Formaldehyde released from N,N-Methylenebismorpholine as an existing active substance for use in biocidal products for product-types 6 and 13 <sup>(1)</sup> is to be incorporated into the EEA Agreement.
- (2) Commission Implementing Regulation (EU) 2015/1982 of 4 November 2015 approving hexaflumuron as an existing active substance for use in biocidal products for product-type 18 <sup>(2)</sup> is to be incorporated into the EEA Agreement.
- (3) Commission Implementing Decision (EU) 2015/1985 of 4 November 2015 pursuant to Article 3(3) of Regulation (EU) No 528/2012 of the European Parliament and of the Council on an anti-viral tissue impregnated with citric acid <sup>(3)</sup> is to be incorporated into the EEA Agreement.
- (4) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

*Article 1*

The following points are inserted after point 12nns (Commission Implementing Regulation (EU) 2015/1759) of Chapter XV of Annex II to the EEA Agreement:

- 12nnt. **32015 R 1981:** Commission Implementing Regulation (EU) 2015/1981 of 4 November 2015 approving Formaldehyde released from N,N-Methylenebismorpholine as an existing active substance for use in biocidal products for product-types 6 and 13 (OJ L 289, 5.11.2015, p. 9).
- 12nnu. **32015 R 1982:** Commission Implementing Regulation (EU) 2015/1982 of 4 November 2015 approving hexaflumuron as an existing active substance for use in biocidal products for product-type 18 (OJ L 289, 5.11.2015, p. 13).
- 12nnv. **32015 D 1985:** Commission Implementing Decision (EU) 2015/1985 of 4 November 2015 pursuant to Article 3(3) of Regulation (EU) No 528/2012 of the European Parliament and of the Council on an anti-viral tissue impregnated with citric acid (OJ L 289, 5.11.2015, p. 26).'

*Article 2*

The texts of Implementing Regulations (EU) 2015/1981 and (EU) 2015/1982 and Implementing Decision (EU) 2015/1985 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

<sup>(1)</sup> OJ L 289, 5.11.2015, p. 9.

<sup>(2)</sup> OJ L 289, 5.11.2015, p. 13.

<sup>(3)</sup> OJ L 289, 5.11.2015, p. 26.

*Article 3*

This Decision shall enter into force on 6 February 2016, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (\*).

*Article 4*

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

Done at Brussels, 5 February 2016.

*For the EEA Joint Committee*

*The President*

Claude MAERTEN

---

(\*) No constitutional requirements indicated.